Burning Rock
Burning Rock Biotech focuses on providing individualized cancer treatment guidance for the patients.
Burning Rock, founded in March, 2014 and headquartered in Beijing, is a tumor precision individualized medical clinical testing service organization. Established by Han Yusheng, Xu Shaokun and Wu Zhigang, the company has received financings from LYFE Capital, Sequoia Capital, Legend Star and so on. Rivals that have direct and indirect competition with Burning Rock globally include Yahui Biotechnology, Autobio, Danaher, etc.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
East China medicine "liraglutide" goes to sea
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
The early-stage cancer-detection technology has declared its mission: to take on and defeat the fatal illness, for the benefit of humanity. Following Burning Rock and Genetron Health, the US biotech GRAIL looks to go public on Nasdaq.
Sep 10, 2020 11:48 AM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Burning Rock Hits NASDAQ, Still Struggles to Make a Profit
NASDAQ welcomes its first Chinese NGS cancer detection company, Burning Rock. The company owns the largest market share in Chinese NGS market but still hasn’t begun to profit. What is the cause and how long does it still need?
Jun 19, 2020 10:20 AM
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Mojia biology announced the completion of round B financing
First class recall of Draeger, a ventilator giant
The state plans to prohibit third-party platforms from directly participating in online drug sales